[Federal Register: April 20, 2010 (Volume 75, Number 75)]
[Notices]
[Page 20603-20604]
[DOCID:fr20ap10-67]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0185]

Agency Information Collection Activities; Proposed Collection;
Comment Request; Tobacco Health Document Submission

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the proposed extension of an
existing collection of information pertaining to the submission of
tobacco health documents under the Family Smoking Prevention and
Tobacco Control Act (the Tobacco Control Act).

DATES:  Submit written or electronic comments on the collection of
information by June 21, 2010.

ADDRESSES:  Submit electronic comments on the collection of information
to http://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Information
Management, Food and Drug Administration, 1350 Piccard Dr., PI50
Rockville, MD 20850,<PHONE_NUMBER>, Email:
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.

    With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.

Title: Tobacco Health Document Submission (OMB Control Number 0910-
0654)--Extension

    On June 22, 2009, the President signed the Tobacco Control Act
(Public Law 111-31) into law. The Tobacco Control Act granted FDA
important new authority to regulate the manufacture, marketing, and
distribution of tobacco products to protect the public health generally
and to reduce tobacco use by minors. Among its many provisions, the
Tobacco Control Act added section 904(a)(4) to the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C. 387d(a)(4)), requiring submission
of documents related to certain effects of tobacco products.
    Section 904(a)(4) of the act requires each tobacco product
manufacturer or importer, or agent thereof, to submit all documents
developed after June 22, 2009 ``that relate to health, toxicological,
behavioral, or physiologic effects of current or future tobacco
products, their constituents (including smoke constituents),
ingredients, components, and additives.'' Information required under
section 904(a)(4) of the act must be submitted to FDA beginning
December 22, 2009.
    FDA issued a draft guidance document entitled, ``Tobacco Health
Document Submission'' on December 28, 2009 (74 FR 68629) to assist
persons making certain document submissions to FDA under section
904(a)(4) of the act. While electronic submission of tobacco health
documents is not required, FDA designed the eSubmitter application as
an alternative for mailing documents. This electronic tool allows for
importation of large quantities of structured data, attachments of
files (e.g., in portable document format (PDFs) and certain media
files), and automatic acknowledgement of FDA's receipt of submissions.
FDA also is developing a paper form (FDA Form 3743) as an alternative
submission tool. Both the eSubmitter application and the paper form can
be accessed at http://www.fda.gov/tobacco once they are complete.
    On September 1, 2009 (74 FR 45219), FDA published notice in the
Federal Register announcing that a proposed collection of information
had been submitted to OMB for emergency processing under the Paperwork
Reduction Act of 1995. On September 15, 2009 (74 FR 47257), FDA
published a notice correcting the length of the comment period, keeping
it open until October 1, 2009. On October 13, 2009 (74 FR 52495), FDA
published a notice reopening the comment period until October 26, 2009.
On January 7, 2010, FDA received emergency approval for this
information collection. Based on comments indicating that the burden
estimate was too low, FDA has adjusted its original burden estimate
from 1.0 hour per response to 200 hours per response. FDA also
increased the annual frequency per response from 1 to 4 (quarterly).
FDA is maintaining the original estimate of the number of respondents
at 10. FDA is basing its estimates on the total number of tobacco firms
it is aware of, its experience with document production, and comments
received in response to the draft guidance document published on
December 28, 2009.
    FDA estimates the burden of this collection of information as
follows:

                                 Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
                                    Annual Frequency      Total Annual          Hours  per
  Activity    No. of Respondents      per Response          Responses            Response         Total Hours
----------------------------------------------------------------------------------------------------------------
Tobacco                        10                  4                    40                200              8,000
 Health
 Document
 Submission
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.

    Dated: April 14, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-8976 Filed 4-19-10; 8:45 am]
BILLING CODE 4160-01-S


[Federal Register Volume 88, Number 150 (Monday, August 7, 2023)]
[Notices]
[Pages 52155-52156]
[FR Doc No: 2023-16784]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER23-2520-000]

SR Litchfield, LLC; Supplemental Notice That Initial Market-Based
Rate Filing Includes Request for Blanket Section 204 Authorization

    This is a supplemental notice in the above-referenced proceeding of
SR Litchfield, LLC's application for market-based rate authority, with
an accompanying rate tariff, noting that such application includes a
request for blanket authorization, under 18 CFR part 34, of future
issuances of securities and assumptions of liability.
    Any person desiring to intervene or to protest should file with the
Federal Energy Regulatory Commission, 888 First Street NE, Washington,
DC 20426, in accordance with Rules 211 and 214 of the Commission's
Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Anyone
filing a motion to intervene or protest must serve a copy of that
document on the Applicant.
    Notice is hereby given that the deadline for filing protests with
regard to the applicant's request for blanket authorization, under 18
CFR part 34, of future issuances of securities and assumptions of
liability, is August 21, 2023.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with internet
access who will eFile a document and/or be listed as a contact for an
intervenor must create and validate an eRegistration account using the
eRegistration link. Select the eFiling link to log on and submit the
intervention or protests.
    Persons unable to file electronically may mail similar pleadings to
the

Federal Energy Regulatory Commission, 888 First Street NE, Washington,
DC 20426. Hand delivered submissions in docketed proceedings should be
delivered to Health and Human Services, 12225 Wilkins Avenue,
Rockville, Maryland 20852.
    In addition to publishing the full text of this document in the
Federal Register, the Commission provides all interested persons an
opportunity to view and/or print the contents of this document via the
internet through the Commission's Home Page (http://www.ferc.gov) using
the ``eLibrary'' link. Enter the docket number excluding the last three
digits in the docket number field to access the document. At this time,
the Commission has suspended access to the Commission's Public
Reference Room, due to the proclamation declaring a National Emergency
concerning the Novel Coronavirus Disease (COVID-19), issued by the
President on March 13, 2020. For assistance, contact the Federal Energy
Regulatory Commission at [email protected] or call toll-free,
(886) 208-3676 or TYY,<PHONE_NUMBER>.
    The Commission's Office of Public Participation (OPP) supports
meaningful public engagement and participation in Commission
proceedings. OPP can help members of the public, including landowners,
environmental justice communities, Tribal members and others, access
publicly available information and navigate Commission processes. For
public inquiries and assistance with making filings such as
interventions, comments, or requests for rehearing, the public is
encouraged to contact OPP at<PHONE_NUMBER> or [email protected].

    Dated: August 1, 2023.
Debbie-Anne A. Reese,
Deputy Secretary.
[FR Doc. 2023-16784 Filed 8-4-23; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register: December 2, 2010 (Volume 75, Number 231)]
[Notices]
[Page 75175-75176]
[DOCID:fr02de10-21]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0603]

Agency Information Collection Activities; Proposed Collection;
Comment Request; Animal Drug User Fees and Fee Waivers and Reductions

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the reporting requirements for
the

animal drug user fees and fee waivers and reductions.

DATES: Submit either electronic or written comments on the collection
of information by January 31, 2011.

ADDRESSES: Submit electronic comments on the collection of information
to http://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Johnny Vilela, Office of Information
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B,
Rockville, MD 20850,<PHONE_NUMBER><EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
    With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.

Animal Drug User Fees and Fee Waivers and Reductions--(OMB Control
Number 0910-0540--Extension)

    Enacted on November 18, 2003, the Animal Drug User Fee Act (ADUFA)
(Pub. L. 108-130) amended the Federal Food, Drug, and Cosmetic Act and
requires FDA to assess and collect user fees for certain applications,
products, establishments, and sponsors. It also requires the Agency to
grant a waiver from, or a reduction of those fees in certain
circumstances. Thus, to implement this statutory provision of ADUFA,
FDA developed a guidance entitled ``Guidance for Industry: Animal Drug
User Fees and Fee Waivers and Reductions.'' It provides guidance on the
types of fees FDA is authorized to collect under ADUFA, and on how to
request waivers and reductions from FDA's animal drug user fees. The
guidance also describes the types of fees and fee waivers and
reductions, the information FDA recommends respondents submit in
support of a request for a fee waiver or reduction, how respondents may
submit such a request, and FDA's process for reviewing requests.
    Respondents to this collection of information are new animal drug
sponsors. Requests for waivers or reductions may be submitted by a
person paying any of the animal drug user fees assessed--application
fees, product fees, establishment fees, or sponsor fees.
    FDA estimates the burden of this collection of information as
follows:

                                 Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
                                                      Annual
         21 CFR Section              Number of     frequency per   Total annual      Hours per      Total hours
                                    respondents      response        responses       response
----------------------------------------------------------------------------------------------------------------
740(d)(1)(A) Significant barrier              22               1              22               2              44
 to innovation..................
740(d)(1)(B) Fees exceed cost...               0               1               0               2               0
740(d)(1)(C) Free choice feeds..               2               1               2               2               4
740(d)(1)(D) Minor use or minor               52               1              52               2             104
 species........................
740(d)(1)(E) Small business.....               0               1               0               0               0
Request for reconsideration of a               5               1               5               2              10
 decision.......................
Request for review--(user fee                  2               1               2               2               4
 appeal officer)................
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............  ..............  ..............             166
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.

    Based on FDA's database system, there are an estimated 250 sponsors
of products subject to ADUFA. However, not all sponsors will have any
submissions in a given year and some may have multiple submissions. The
total number of waiver requests is based on the number of submission
types received by FDA in fiscal year 2008.

    Dated: November 24, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-30264 Filed 12-1-10; 8:45 am]
BILLING CODE 4160-01-P


[Federal Register Volume 83, Number 166 (Monday, August 27, 2018)]
[Notices]
[Pages 43715-43720]
[FR Doc No: 2018-18427]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Investment Company Act Release No. 33205; File No. 812-14839]

Tortoise Capital Advisors, L.L.C., et al.

August 21, 2018.
AGENCY: Securities and Exchange Commission (``Commission'').

ACTION: Notice.

-----------------------------------------------------------------------

    Notice of application for an order under sections 17(d) and 57(i)
of the Investment Company Act of 1940 (the ``Act'') and rule 17d-1
under the Act to permit certain joint transactions otherwise prohibited
by sections 17(d) and 57(a)(4) of the Act and rule 17d-1 under the Act.

SUMMARY OF APPLICATION: Applicants request an order to permit certain
business development companies (``BDC'') and closed-end management
investment companies to co-invest in portfolio companies with each
other and with affiliated investment funds.

APPLICANTS: Tortoise Energy Infrastructure Corporation (``Energy
Infrastructure Corp.''), Tortoise MLP Fund, Inc. (``MLP Fund''),
Tortoise Pipeline & Energy Fund, Inc. (``Pipeline Fund''), Tortoise
Energy Independence Fund, Inc. (``Independence Fund''), Tortoise Power
and Energy Infrastructure Fund, Inc. (``Power Fund''), Tortoise
Essential Assets Income 2024 Term Fund, Inc. (``Income Fund''),
Tortoise Tax-Advantaged Social Infrastructure Fund, Inc. (``Social
Infrastructure Fund'' and together with Energy Infrastructure Corp.,
MLP Fund, Pipeline Fund, Independence Fund, Power Fund, and Income
Fund, the ``Existing Regulated Funds''), Tortoise Capital Advisors,
L.L.C. (``Tortoise Advisors''), on behalf of itself and its successors,
Tortoise Direct Opportunities Fund, LP (``DO Fund''), Tortoise Direct
Opportunities Fund II, LP (``DO Fund II''), Tortoise Direct Municipal
Opportunities Fund, LP (``Municipal Fund'' and, together with DO Fund
and DO Fund II, the ``Existing Affiliated Funds''), and Tortoise Credit
Strategies, LLC (the ``Existing Affiliated Adviser'').

FILING DATES: The application was filed on November 7, 2017, and
amended on March 29, 2018, and August 1, 2018.

HEARING OR NOTIFICATION OF HEARING: An order granting the requested
relief will be issued unless the Commission orders a hearing.
Interested persons may request a hearing by writing to the Commission's
Secretary and serving applicants with a copy of the request, personally
or by mail. Hearing requests should be received by the Commission by
5:30 p.m. on September 17, 2018, and should be accompanied by proof of
service on applicants, in the form of an affidavit or, for lawyers, a
certificate of service. Pursuant to rule 0-5 under the Act, hearing
requests should state the nature of the writer's interest, any facts
bearing upon the desirability of a hearing on the matter, the reason
for the request, and the issues contested. Persons who wish to be
notified of a hearing may request notification by writing to the
Commission's Secretary.

ADDRESSES: Secretary, U.S. Securities and Exchange Commission, 100 F
St. NE, Washington, DC 20549-1090. Applicants, 11550 Ash Street, Suite
300, Leawood, KS 66211.

FOR FURTHER INFORMATION CONTACT: Christine Y. Greenlees, Senior
Counsel, at<PHONE_NUMBER> or Andrea Ottomanelli Magovern, Branch
Chief, at<PHONE_NUMBER> (Chief Counsel's Office, Division of
Investment Management).

SUPPLEMENTARY INFORMATION: The following is a summary of the
application. The complete application may be obtained via the
Commission's website by searching for the file number, or for an
applicant using the Company name box, at http://www.sec.gov/search/search.htm or by calling<PHONE_NUMBER>.
    Applicants' Representations:
    1. Energy Infrastructure Corp. was organized as a Maryland
corporation for the purpose of operating as an externally-managed, non-
diversified, closed-end management investment company. Energy
Infrastructure Corp. is a registered investment company under the Act.
Energy Infrastructure Corp.'s Objectives and Strategies \1\ are to seek
a high level of total return with an emphasis on current distributions
primarily through investments in publicly traded master limited
partnerships (``MLPs'') and their affiliates in the energy
infrastructure sector. Energy Infrastructure Corp. has a six member
Board,\2\ of which four members are Non-Interested Directors.\3\
---------------------------------------------------------------------------

    \1\ ``Objectives and Strategies'' means a Regulated Fund's
investment objectives and strategies, as described in the Regulated
Fund's registration statement on Form N-2, other filings the
Regulated Fund has made with the Commission under the Securities Act
of 1933 (the ``Securities Act''), or under the Securities Exchange
Act of 1934, and the Regulated Fund's reports to shareholders.
    \2\ The term ``Board'' refers to the board of directors of any
Regulated Fund.
    \3\ The term ``Non-Interested Directors'' refers to the
directors of any Regulated Fund that are not ``interested persons''
of the Regulated Fund within the meaning of section 2(a)(19) of the
Act.
---------------------------------------------------------------------------

    2. MLP Fund was organized as a Maryland corporation for the purpose
of operating as an externally-managed, non-diversified, closed-end
management investment company. MLP Fund is a registered investment
company under the Act. MLP Fund's Objectives and Strategies are to seek
a high level of total return with an emphasis on current distributions
primarily through investments in energy MLPs and their affiliates, with
an emphasis on natural gas infrastructure MLPs. MLP Fund has a six
member Board, of which four members are Non-Interested Directors.
    3. Pipeline Fund was organized as a Maryland corporation for the
purpose of operating as an externally-managed, non-diversified, closed-
end management investment company. Pipeline Fund is a registered
investment company under the Act. Pipeline Fund has elected to be
treated, and intends to comply with the requirements to continue to
qualify annually, as a regulated investment company (``RIC'') under the
Internal Revenue Code of 1986, as amended (the ``Code''), and intends
to continue to make such election in the future. Pipeline Fund's
Objectives and Strategies are to seek a high level of total return with
an emphasis on current distributions primarily through investments in
equity securities of North American pipeline companies that transport
natural gas,

natural gas liquids, crude oil and refined products, and other energy
infrastructure companies. Pipeline Fund has a six member Board, of
which four members are Non-Interested Directors.
    4. Independence Fund was organized as a Maryland corporation for
the purpose of operating as an externally-managed, non-diversified,
closed-end management investment company. Independence Fund is a
registered investment company under the Act. Independence Fund has
elected to be treated, and intends to comply with the requirements to
continue to qualify annually, as a RIC under the Code, and intends to
continue to make such election in the future. Independence Fund's
Objectives and Strategies are to seek a high level of total return with
an emphasis on current distributions primarily through investments in
North American energy companies that engage in the exploration and
production of crude oil, condensate, natural gas and natural gas
liquids that generally have a strong presence in North American oil and
gas reservoirs, including shale, and, to a lesser extent, on companies
that provide associated transportation, processing, storage, servicing
and equipment. Independence Fund has a six member Board, of which four
members are Non-Interested Directors.
    5. Power Fund was organized as a Maryland corporation for the
purpose of operating as an externally-managed, non-diversified, closed-
end management investment company. Power Fund is a registered
investment company under the Act. Power Fund has elected to be treated,
and intends to comply with the requirements to continue to qualify
annually, as a RIC under the Code, and intends to continue to make such
election in the future. Power Fund's Objectives and Strategies are to
seek a high level of current income, with a secondary objective of
capital appreciation primarily through investments in income-producing
fixed income and equity securities issued by power and energy
infrastructure companies. Power Fund has a six member Board, of which
four members are Non-Interested Directors.
    6. Income Fund was organized as a Maryland corporation for the
purpose of operating as an externally-managed, non-diversified, closed-
end management investment company. Income Fund is a registered
investment company under the Act. Income Fund has elected to be
treated, and intends to comply with the requirements to continue to
qualify annually, as a RIC under the Code, and intends to continue to
make such election in the future. Income Fund's Objectives and
Strategies are to seek a high level of current income, with a secondary
objective of capital appreciation primarily through investments in
corporate debt securities, and private investments. Income Fund has a
six member Board, of which four members are Non-Interested Directors.
    7. Social Infrastructure Fund was organized as a Maryland
corporation for the purpose of operating as an externally-managed, non-
diversified, closed-end management investment company. Social
Infrastructure Fund is a registered investment company under the Act.
Social Infrastructure Fund has elected to be treated, and intends to
comply with the requirements to continue to qualify annually, as a RIC
under the Code, and intends to continue to make such election in the
future. Social Infrastructure Fund's Objectives and Strategies are to
seek a high level of total return with an emphasis on tax-advantaged
income primarily through investments in the social infrastructure
sector. Social Infrastructure Fund has a four member Board, of which
three members are Non-Interested Directors.
    8. Each of the Existing Affiliated Funds was organized as a
Delaware limited partnership and would be an investment company but for
section 3(c)(7) of the Act. Each Existing Affiliated Fund has
investment objectives and policies that are similar to those of the
Existing Regulated Funds.
    9. Tortoise Advisors is a Delaware limited liability company and is
registered as an investment adviser under the Investment Advisers Act
of 1940 (the ``Advisers Act''). Tortoise Advisors is wholly-owned by
Tortoise Investments, LLC. Lovell Minnick Partners LLC (``Lovell
Minnick'') owns a majority interest in Tortoise Investments, LLC
(``Tortoise''). An entity formed by Lovell Minnick owned by certain
private funds sponsored by Lovell Minnick and a group of institutional
co-investors owns a controlling interest in Tortoise. Certain employees
in the Tortoise complex also own interests in Tortoise. Tortoise
Advisors serves as investment adviser to Energy Infrastructure Corp.,
MLP Fund, Pipeline Fund, Independence Fund, Power Fund, DO Fund, and DO
Fund II.
    10. The Existing Affiliated Adviser is a Delaware limited liability
company and is registered as an investment adviser under the Advisers
Act. The Existing Affiliated Adviser is privately held and is an
affiliate of, and under common control with, Tortoise Advisors. The
Existing Affiliated Adviser serves as investment adviser to Income
Fund, Social Infrastructure Fund, and Municipal Fund.
    11. Applicants seek an order (``Order'') to permit one or more
Regulated Funds \4\ and/or one or more Affiliated Funds \5\ to
participate in the same investment opportunities through a proposed co-
investment program (the ``Co-Investment Program'') where such
participation would otherwise be prohibited under sections 17(d) and
57(a)(4) and rule 17d-1 by (a) co-investing with each other in
securities issued by issuers in private placement transactions in which
an Adviser negotiates terms in addition to price; \6\ and (b) making
additional investments in securities of such issuers, including through
the exercise of warrants, conversion privileges, and other rights to
purchase securities of the issuers (``Follow-On Investments''). ``Co-
Investment Transaction'' means any transaction in which a Regulated
Fund (or its Wholly-Owned Investment Sub, as defined below)
participated together with one or more other Regulated Funds and/or one
or more Affiliated Funds in reliance on the requested Order.
``Potential Co-Investment Transaction'' means any investment
opportunity in which a Regulated Fund (or its Wholly-Owned Investment
Sub) could not participate together with one or more Affiliated Funds
and/or one or more other Regulated Funds without obtaining and relying
on the Order.\7\
---------------------------------------------------------------------------

    \4\ ``Regulated Fund'' means the Existing Regulated Funds and
any Future Regulated Fund. ``Future Regulated Fund'' means any
closed-end management investment company (a) that is registered
under the Act or has elected to be regulated as a BDC, (b) whose
investment adviser is an Adviser, and (c) that intends to
participate in the Co-Investment Program. The term ``Adviser'' means
(a) Tortoise Advisors, (b) the Existing Affiliated Adviser, and (c)
any future investment adviser that is controlled by Tortoise
Advisors and is registered under the Advisers Act.
    \5\ ``Affiliated Fund'' means (a) the Existing Affiliated Funds
and (b) any Future Affiliated Fund. ``Future Affiliated Fund'' means
any entity (a) whose investment adviser is an Adviser, (b) that
would be an investment company but for section 3(c)(1) or 3(c)(7) of
the Act, and (c) that intends to participate in the Co-Investment
Program.
    \6\ The term ``private placement transactions'' means
transactions in which the offer and sale of securities by the issuer
are exempt from registration under the Securities Act.
    \7\ All existing entities that currently intend to rely upon the
requested Order have been named as applicants. Any other existing or
future entity that subsequently relies on the Order will comply with
the terms and conditions of the application.
---------------------------------------------------------------------------

    12. Applicants state that a Regulated Fund may, from time to time,
form a Wholly-Owned Investment Sub.\8\ Such a

subsidiary would be prohibited from investing in a Co-Investment
Transaction with any Affiliated Fund or Regulated Fund because it would
be a company controlled by its parent Regulated Fund for purposes of
section 57(a)(4) and rule 17d-1. Applicants request that each Wholly-
Owned Investment Sub be permitted to participate in Co-Investment
Transactions in lieu of its parent Regulated Fund and that the Wholly-
Owned Investment Sub's participation in any such transaction be
treated, for purposes of the requested Order, as though the parent
Regulated Fund were participating directly. Applicants represent that
this treatment is justified because a Wholly-Owned Investment Sub would
have no purpose other than serving as a holding vehicle for the
Regulated Fund's investments and, therefore, no conflicts of interest
could arise between the Regulated Fund and the Wholly-Owned Investment
Sub. The Regulated Fund's Board would make all relevant determinations
under the conditions with regard to a Wholly-Owned Investment Sub's
participation in a Co-Investment Transaction, and the Regulated Fund's
Board would be informed of, and take into consideration, any proposed
use of a Wholly-Owned Investment Sub in the Regulated Fund's place. If
the Regulated Fund proposes to participate in the same Co-Investment
Transaction with any of its Wholly-Owned Investment Subs, the Board
will also be informed of, and take into consideration, the relative
participation of the Regulated Fund and the Wholly-Owned Investment
Sub.
---------------------------------------------------------------------------

    \8\ The term ``Wholly-Owned Investment Sub'' means an entity (i)
that is wholly-owned by a Regulated Fund (with the Regulated Fund at
all times holding, beneficially and of record, 100% of the voting
and economic interests); (ii) whose sole business purpose is to hold
one or more investments on behalf of the Regulated Fund; (iii) with
respect to which the Regulated Fund's Board has the sole authority
to make all determinations with respect to the entity's
participation under the conditions of the application; and (iv) that
would be an investment company but for section 3(c)(1) or 3(c)(7) of
the Act. Any future subsidiaries of the Regulated Funds that
participate in Co-Investment Transactions will be Wholly-Owned
Investment Subs.
---------------------------------------------------------------------------

    13. When considering Potential Co-Investment Transactions for any
Regulated Fund, the applicable Adviser will consider only the
Objectives and Strategies, investment policies, investment positions,
capital available for investment (``Available Capital''), and other
pertinent factors applicable to that Regulated Fund. The Advisers
expect that any portfolio company that is an appropriate investment for
a Regulated Fund should also be an appropriate investment for one or
more other Regulated Funds and/or one or more Affiliated Funds, with
certain exceptions based on Available Capital or diversification. The
Regulated Funds, however, will not be obligated to invest, or co-
invest, when investment opportunities are referred to them.
    14. Other than pro rata dispositions and Follow-On Investments as
provided in conditions 7 and 8, and after making the determinations
required in conditions 1 and 2(a), the Adviser will present each
Potential Co-Investment Transaction and the proposed allocation to the
directors of the Board eligible to vote under section 57(o) of the Act
(``Eligible Directors''), and the ``required majority,'' as defined in
section 57(o) of the Act (``Required Majority'') \9\ will approve each
Co-Investment Transaction prior to any investment by the participating
Regulated Fund.
---------------------------------------------------------------------------

    \9\ In the case of a Regulated Fund that is a registered closed-
end fund, the Board members that make up the Required Majority will
be determined as if the Regulated Fund were a BDC subject to section
57(o).
---------------------------------------------------------------------------

    15. With respect to the pro rata dispositions and Follow-On
Investments provided in conditions 7 and 8, a Regulated Fund may
participate in a pro rata disposition or Follow-On Investment without
obtaining prior approval of the Required Majority if, among other
things: (i) The proposed participation of each Regulated Fund and
Affiliated Fund in such disposition is proportionate to its outstanding
investments in the issuer immediately preceding the disposition or
Follow-On Investment, as the case may be; and (ii) the Board of the
Regulated Fund has approved that Regulated Fund's participation in pro
rata dispositions and Follow-On Investments as being in the best
interests of the Regulated Fund. If the Board does not so approve, any
such disposition or Follow-On Investment will be submitted to the
Regulated Fund's Eligible Directors. The Board of any Regulated Fund
may at any time rescind, suspend or qualify its approval of pro rata
dispositions and Follow-On Investments with the result that all
dispositions and/or Follow-On Investments must be submitted to the
Eligible Directors.
    16. No Non-Interested Director of a Regulated Fund will have a
financial interest in any Co-Investment Transaction, other than
indirectly through share ownership in one of the Regulated Funds.
    17. Under condition 14, if an Adviser or its principal owners (the
``Principals''), or any person controlling, controlled by, or under
common control with an Adviser or the Principals, and the Affiliated
Funds (collectively, the ``Holders'') own in the aggregate more than
25% of the outstanding voting shares of a Regulated Fund (the
``Shares''), then the Holders will vote such Shares as directed by an
independent third party when voting on matters specified in the
condition. Applicants believe that this condition will ensure that the
Non-Interested Directors will act independently in evaluating the Co-
Investment Program, because the ability of an Adviser or the Principals
to influence the Non-Interested Directors by a suggestion, explicit or
implied, that the Non-Interested Directors can be removed will be
limited significantly. Applicants represent that the Non-Interested
Directors will evaluate and approve any such independent party, taking
into account its qualifications, reputation for independence, cost to
the shareholders, and other factors that they deem relevant.
    Applicants' Legal Analysis:
    1. Section 17(d) of the Act and rule 17d-1 under the Act prohibit
participation by a registered investment company and an affiliated
person in any ``joint enterprise or other joint arrangement or profit-
sharing plan,'' as defined in the rule, without prior approval by the
Commission by order upon application. Section 17(d) of the Act and rule
17d-1 under the Act are applicable to Regulated Funds that are
registered closed-end investment companies. Similarly, with regard to
BDCs, section 57(a)(4) of the Act generally prohibits certain persons
specified in section 57(b) from participating in joint transactions
with the BDC or a company controlled by the BDC in contravention of
rules as prescribed by the Commission. Section 57(i) of the Act
provides that, until the Commission prescribes rules under section
57(a)(4), the Commission's rules under section 17(d) of the Act
applicable to registered closed-end investment companies will be deemed
to apply to transactions subject to section 57(a)(4). Because the
Commission has not adopted any rules under section 57(a)(4), rule 17d-1
also applies to joint transactions with Regulated Funds that are BDCs.
    2. In passing upon applications under rule 17d-1, the Commission
considers whether the company's participation in the joint transaction
is consistent with the provisions, policies, and purposes of the Act
and the extent to which such participation is on a basis different from
or less advantageous than that of other participants.
    3. Applicants submit that Tortoise Advisors and the Existing
Affiliated Adviser may be deemed to control the Existing Regulated
Funds and the Existing Affiliated Funds, respectively, and any other
Adviser will be controlling, controlled by, or under common control
with Tortoise Advisors.

As a result, the Regulated Funds may be deemed to be under common
control, and thus affiliated persons of each other under section
2(a)(3)(C) of the Act. In addition, the Affiliated Funds may be deemed
to be under common control with the Regulated Funds, and thus
affiliated persons of each Regulated Fund under section 2(a)(3)(C) of
the Act. As a result, these relationships might cause a Regulated Fund
and one or more other Regulated Funds and/or one or more Affiliated
Funds participating in Co-Investment Transactions to be subject to
section 17(d) or 57(a)(4) of the Act, and thus subject to the
provisions of rule 17d-1 of the Act.
    4. Applicants state that in the absence of the requested relief, in
some circumstances the Regulated Funds would be limited in their
ability to participate in attractive and appropriate investment
opportunities. Applicants believe that the proposed terms and
conditions of the application will ensure that the Co-Investment
Transactions are consistent with the protection of each Regulated
Fund's shareholders and with the purposes intended by the policies and
provisions of the Act. Applicants state that the Regulated Funds'
participation in the Co-Investment Transactions will be consistent with
the provisions, policies, and purposes of the Act and would be done in
a manner that is not different from, or less advantageous than, that of
other participants.
Applicants' Conditions:
    Applicants agree that the Order will be subject to the following
conditions:
    1. Each time an Adviser considers a Potential Co-Investment
Transaction for an Affiliated Fund or another Regulated Fund that falls
within a Regulated Fund's then-current Objectives and Strategies, the
Regulated Fund's Adviser will make an independent determination of the
appropriateness of the investment for such Regulated Fund in light of
the Regulated Fund's then-current circumstances.
    2. (a) If the Adviser deems a Regulated Fund's participation in any
Potential Co-Investment Transaction to be appropriate for the Regulated
Fund, it will then determine an appropriate level of investment for the
Regulated Fund.
    (b) If the aggregate amount recommended by the applicable Adviser
to be invested by the applicable Regulated Fund in the Potential Co-
Investment Transaction, together with the amount proposed to be
invested by the other participating Regulated Funds and Affiliated
Funds, collectively, in the same transaction, exceeds the amount of the
investment opportunity, the investment opportunity will be allocated
among them pro rata based on each participant's Available Capital, up
to the amount proposed to be invested by each. The applicable Adviser
will provide the Eligible Directors of each participating Regulated
Fund with information concerning each participating party's Available
Capital to assist the Eligible Directors with their review of the
Regulated Fund's investments for compliance with these allocation
procedures.
    (c) After making the determinations required in conditions 1 and
2(a), the applicable Adviser will distribute written information
concerning the Potential Co-Investment Transaction (including the
amount proposed to be invested by each participating Regulated Fund and
Affiliated Fund) to the Eligible Directors of each participating
Regulated Fund for their consideration. A Regulated Fund will co-invest
with one or more other Regulated Funds and/or one or more Affiliated
Funds only if, prior to the Regulated Fund's participation in the
Potential Co-Investment Transaction, a Required Majority concludes
that:
    (i) the terms of the Potential Co-Investment Transaction, including
the consideration to be paid, are reasonable and fair to the Regulated
Fund and its shareholders and do not involve overreaching in respect of
the Regulated Fund or its shareholders on the part of any person
concerned;
    (ii) the Potential Co-Investment Transaction is consistent with:
    (A) the interests of the shareholders of the Regulated Fund; and
    (B) the Regulated Fund's then-current Objectives and Strategies;
    (iii) the investment by any other Regulated Funds or Affiliated
Funds would not disadvantage the Regulated Fund, and participation by
the Regulated Fund would not be on a basis different from or less
advantageous than that of other Regulated Funds or Affiliated Funds;
provided that, if any other Regulated Fund or Affiliated Fund, but not
the Regulated Fund itself, gains the right to nominate a director for
election to a portfolio company's board of directors or the right to
have a board observer or any similar right to participate in the
governance or management of the portfolio company, such event shall not
be interpreted to prohibit the Required Majority from reaching the
conclusions required by this condition (2)(c)(iii), if:
    (A) the Eligible Directors will have the right to ratify the
selection of such director or board observer, if any;
    (B) the applicable Adviser agrees to, and does, provide periodic
reports to the Regulated Fund's Board with respect to the actions of
such director or the information received by such board observer or
obtained through the exercise of any similar right to participate in
the governance or management of the portfolio company; and
    (C) any fees or other compensation that any Affiliated Fund or any
Regulated Fund or any affiliated person of any Affiliated Fund or any
Regulated Fund receives in connection with the right of the Affiliated
Fund or a Regulated Fund to nominate a director or appoint a board
observer or otherwise to participate in the governance or management of
the portfolio company will be shared proportionately among the
participating Affiliated Funds (who each may, in turn, share its
portion with its affiliated persons) and the participating Regulated
Funds in accordance with the amount of each party's investment; and
    (iv) the proposed investment by the Regulated Fund will not benefit
the Advisers, the Affiliated Funds or the other Regulated Funds or any
affiliated person of any of them (other than the parties to the Co-
Investment Transaction), except (A) to the extent permitted by
condition 13, (B) to the extent permitted by Section 17(e) or 57(k) of
the Act, as applicable, (C) indirectly, as a result of an interest in
the securities issued by one of the parties to the Co-Investment
Transaction, or (D) in the case of fees or other compensation described
in condition 2(c)(iii)(C).
    3. Each Regulated Fund has the right to decline to participate in
any Potential Co-Investment Transaction or to invest less than the
amount proposed.
    4. The applicable Adviser will present to the Board of each
Regulated Fund, on a quarterly basis, a record of all investments in
Potential Co-Investment Transactions made by any of the other Regulated
Funds or Affiliated Funds during the preceding quarter that fell within
the Regulated Fund's then-current Objectives and Strategies that were
not made available to the Regulated Fund, and an explanation of why the
investment opportunities were not offered to the Regulated Fund. All
information presented to the Board pursuant to this condition will be
kept for the life of the Regulated Fund and at least two years
thereafter, and will be subject to examination by the Commission and
its staff.
    5. Except for Follow-On Investments made in accordance with
condition 8,\10\

a Regulated Fund will not invest in reliance on the Order in any issuer
in which another Regulated Fund, Affiliated Fund, or any affiliated
person of another Regulated Fund or Affiliated Fund is an existing
investor.
---------------------------------------------------------------------------

    \10\ This exception applies only to Follow-On Investments by a
Regulated Fund in issuers in which that Regulated Fund already holds
investments.
---------------------------------------------------------------------------

    6. A Regulated Fund will not participate in any Potential Co-
Investment Transaction unless the terms, conditions, price, class of
securities to be purchased, settlement date, and registration rights
will be the same for each participating Regulated Fund and Affiliated
Fund. The grant to an Affiliated Fund or another Regulated Fund, but
not the Regulated Fund, of the right to nominate a director for
election to a portfolio company's board of directors, the right to have
an observer on the board of directors or similar rights to participate
in the governance or management of the portfolio company will not be
interpreted so as to violate this condition 6, if conditions
2(c)(iii)(A), (B) and (C) are met.
    7. (a) If any Affiliated Fund or any Regulated Fund elects to sell,
exchange or otherwise dispose of an interest in a security that was
acquired in a Co-Investment Transaction, the applicable Advisers will:
    (i) Notify each Regulated Fund that participated in the Co-
Investment Transaction of the proposed disposition at the earliest
practical time; and
    (ii) formulate a recommendation as to participation by each
Regulated Fund in the disposition.
    (b) Each Regulated Fund will have the right to participate in such
disposition on a proportionate basis, at the same price and on the same
terms and conditions as those applicable to the participating
Affiliated Funds and Regulated Funds.
    (c) A Regulated Fund may participate in such disposition without
obtaining prior approval of the Required Majority if: (i) The proposed
participation of each Regulated Fund and each Affiliated Fund in such
disposition is proportionate to its outstanding investments in the
issuer immediately preceding the disposition; (ii) the Board of the
Regulated Fund has approved as being in the best interests of the
Regulated Fund the ability to participate in such dispositions on a pro
rata basis (as described in greater detail in the application); and
(iii) the Board of the Regulated Fund is provided on a quarterly basis
with a list of all dispositions made in accordance with this condition.
In all other cases, the Adviser will provide its written recommendation
as to the Regulated Fund's participation to the Eligible Directors, and
the Regulated Fund will participate in such disposition solely to the
extent that a Required Majority determines that it is in the Regulated
Fund's best interests.
    (d) Each Affiliated Fund and each Regulated Fund will bear its own
expenses in connection with any such disposition.
    8. (a) If any Affiliated Fund or any Regulated Fund desires to make
a Follow-On Investment in a portfolio company whose securities were
acquired in a Co-Investment Transaction, the applicable Advisers will:
    (i) Notify each Regulated Fund that participated in the Co-
Investment Transaction of the proposed transaction at the earliest
practical time; and
    (ii) formulate a recommendation as to the proposed participation,
including the amount of the proposed Follow-On Investment, by each
Regulated Fund.
    (b) A Regulated Fund may participate in such Follow-On Investment
without obtaining prior approval of the Required Majority if: (i) The
proposed participation of each Regulated Fund and each Affiliated Fund
in such investment is proportionate to its outstanding investments in
the issuer immediately preceding the Follow-On Investment; and (ii) the
Board of the Regulated Fund has approved as being in the best interests
of the Regulated Fund the ability to participate in Follow-On
Investments on a pro rata basis (as described in greater detail in the
application). In all other cases, the Adviser will provide its written
recommendation as to the Regulated Fund's participation to the Eligible
Directors, and the Regulated Fund will participate in such Follow-On
Investment solely to the extent that a Required Majority determines
that it is in the Regulated Fund's best interests.
    (c) If, with respect to any Follow-On Investment:
    (i) The amount of the opportunity is not based on the Regulated
Funds' and the Affiliated Funds' outstanding investments immediately
preceding the Follow-On Investment; and
    (ii) the aggregate amount recommended by the applicable Adviser to
be invested by the applicable Regulated Fund in the Follow-On
Investment, together with the amount proposed to be invested by the
other participating Regulated Funds and Affiliated Funds, collectively,
in the same transaction, exceeds the amount of the investment
opportunity, then the investment opportunity will be allocated among
them pro rata based on each participant's Available Capital, up to the
maximum amount proposed to be invested by each.
    (d) The acquisition of Follow-On Investments as permitted by this
condition will be considered a Co-Investment Transaction for all
purposes and subject to the other conditions set forth in the
application.
    9. The Non-Interested Directors of each Regulated Fund will be
provided quarterly for review all information concerning Potential Co-
Investment Transactions and Co-Investment Transactions, including
investments made by other Regulated Funds or Affiliated Funds that the
Regulated Fund considered but declined to participate in, so that the
Non-Interested Directors may determine whether all investments made
during the preceding quarter, including those investments that the
Regulated Fund considered but declined to participate in, comply with
the conditions of the Order. In addition, the Non-Interested Directors
will consider at least annually the continued appropriateness for the
Regulated Fund of participating in new and existing Co-Investment
Transactions.
    10. Each Regulated Fund will maintain the records required by
section 57(f)(3) of the Act as if each of the Regulated Funds were a
BDC and each of the investments permitted under these conditions were
approved by the Required Majority under section 57(f) of the Act.
    11. No Non-Interested Director of a Regulated Fund will also be a
director, general partner, managing member or principal, or otherwise
an ``affiliated person'' (as defined in the Act) of an Affiliated Fund.
    12. The expenses, if any, associated with acquiring, holding or
disposing of any securities acquired in a Co-Investment Transaction
(including, without limitation, the expenses of the distribution of any
such securities registered for sale under the Securities Act) will, to
the extent not payable by the Advisers under their respective
investment advisory agreements with Affiliated Funds and the Regulated
Funds, be shared by the Regulated Funds and the Affiliated Funds in
proportion to the relative amounts of the securities held or to be
acquired or disposed of, as the case may be.
    13. Any transaction fee \11\ (including break-up or commitment fees
but excluding broker's fees contemplated by section 17(e) or 57(k) of
the Act, as applicable), received in connection with a Co-Investment
Transaction will be distributed to the participating

Regulated Funds and Affiliated Funds on a pro rata basis based on the
amounts they invested or committed, as the case may be, in such Co-
Investment Transaction. If any transaction fee is to be held by an
Adviser pending consummation of the transaction, the fee will be
deposited into an account maintained by such Adviser at a bank or banks
having the qualifications prescribed in section 26(a)(1) of the Act,
and the account will earn a competitive rate of interest that will also
be divided pro rata among the participating Regulated Funds and
Affiliated Funds based on the amounts they invest in such Co-Investment
Transaction. None of the Affiliated Funds, the Advisers, the other
Regulated Funds or any affiliated person of the Regulated Funds or
Affiliated Funds will receive additional compensation or remuneration
of any kind as a result of or in connection with a Co-Investment
Transaction (other than (a) in the case of the Regulated Funds and the
Affiliated Funds, the pro rata transaction fees described above and
fees or other compensation described in condition 2(c)(iii)(C); and (b)
in the case of an Adviser, investment advisory fees paid in accordance
with the agreement between the Adviser and the Regulated Fund or
Affiliated Fund.
---------------------------------------------------------------------------

    \11\ Applicants are not requesting and the staff of the
Commission is not providing any relief for transaction fees received
in connection with any Co-Investment Transaction.
---------------------------------------------------------------------------

    14. If the Holders own in the aggregate more than 25% of the Shares
of a Regulated Fund, then the Holders will vote such Shares as directed
by an independent third party when voting on (1) the election of
directors; (2) the removal of one or more directors; or (3) any other
matter under either the Act or applicable State law affecting the
Board's composition, size or manner of election.
    15. Each Regulated Fund's chief compliance officer, as defined in
rule 38a-1(a)(4), will prepare an annual report for its Board that
evaluates (and documents the basis of that evaluation) the Regulated
Fund's compliance with the terms and conditions of the application and
the procedures established to achieve such compliance.

    For the Commission, by the Division of Investment Management,
under delegated authority.
Eduardo A. Aleman,
Assistant Secretary.
[FR Doc. 2018-18427 Filed 8-24-18; 8:45 am]
 BILLING CODE 8011-01-P


[Federal Register Volume 88, Number 161 (Tuesday, August 22, 2023)]
[Notices]
[Pages 57125-57126]
[FR Doc No: 2023-18039]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID FEMA-2014-0022]

Technical Mapping Advisory Council; Meeting

AGENCY: Federal Emergency Management Agency, Department of Homeland
Security.

ACTION: Notice of Federal advisory committee meeting.

-----------------------------------------------------------------------

SUMMARY: The Federal Emergency Management Agency (FEMA) Technical
Mapping Advisory Council (TMAC) will hold an in-person public meeting
with a virtual option on Tuesday, September 19, 2023, and Wednesday,
September 20, 2023. The meeting will be open to the public in-person
and via a Microsoft Teams Video Communications link.

DATES: The TMAC will meet on Tuesday, September 19, 2023, and
Wednesday, September 20, 2023, from 8:00 a.m. to 5:00 p.m. Eastern Time
(ET). Please note that the meeting will close early if the TMAC has
completed its business.

ADDRESSES: The meeting will be held in-person at the FEMA Conference
Center at 400 C St. SW, Washington, DC 20472. and virtually using the
following Microsoft Teams Video Communications link (Tuesday Link:
https://tinyurl.com/5n7ahwpw; Wednesday Link: https://tinyurl.com/bdjetjb9). Members of the public who wish to attend the in-person or
virtual meeting must register in advance by sending an email to [email protected] (Attn: Brian Koper) by 5:00 p.m. ET on Friday,
September 15, 2023. Members of the public who wish to attend the in-
person or virtual meeting must register in advance by sending an email
to [email protected] (Attn: Brian Koper) by 5:00 p.m. ET on
Friday, September 15, 2023.
    To facilitate public participation, members of the public are
invited to provide written comments on the issues to be considered by
the TMAC, as listed in the SUPPLEMENTARY INFORMATION caption below.
Associated meeting materials will be available upon request after
Wednesday, September 13, 2023. To receive a copy of any relevant
materials, please send the request to: [email protected] (Attn:
Brian Koper). Written comments to be considered by the committee at the
time of the meeting must be submitted and received by Thursday,
September 14, 2023, 5:00 p.m. ET identified by Docket ID FEMA-2014-
0022, and submitted by one of the following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the instructions for submitting comments.
     Email: Address the email to [email protected].
Include the docket number in the subject line of the message. Include
name and contact information in the body of the email.
    Instructions: All submissions received must include the words
``Federal Emergency Management Agency'' and the docket number for this
action. Comments received will be posted without alteration at http://www.regulations.gov, including any personal information provided. You
may wish to review the Privacy and Security Notice via a link on the
homepage of www.regulations.gov.

    Docket: For docket access to read background documents or comments
received by the TMAC, go to http://www.regulations.gov and search for
the Docket ID FEMA-2014-0022.
    A public comment period will be held on Tuesday, September 19,
2023, from 3:30 p.m. to 4:00 p.m. ET and Wednesday, September 20, 2023,
from 12:00 p.m. to 12:30 p.m. ET. The public comment period will not
exceed 30 minutes. Please note that the public comment period may end
before the time indicated, following the last call for comments.
Contact the individual listed below to register as a speaker by
Tuesday, September 12, 2023, 5:00 p.m. ET. Please be prepared to submit
a written version of your public comment.
    FEMA is committed to ensuring all participants have equal access
regardless of disability status. If you require reasonable
accommodation due to a disability to fully participate, please contact
the individual listed in the FOR FURTHER INFORMATION CONTACT caption as
soon as possible.

FOR FURTHER INFORMATION CONTACT: Brian Koper, Designated Federal
Officer for the TMAC, FEMA, 400 C St. SW, Washington, DC 20472,
telephone<PHONE_NUMBER>, and email [email protected]. The TMAC
website is: https://www.fema.gov/flood-maps/guidance-partners/technical-mapping-advisory-council.

SUPPLEMENTARY INFORMATION: Notice of this meeting is given under the
Federal Advisory Committee Act, Public Law 117-286, 5 U.S.C. ch. 10.
    In accordance with the Biggert-Waters Flood Insurance Reform Act of
2012, the TMAC makes recommendations to the FEMA Administrator on: (1)
how to improve, in a cost-effective manner, the (a) accuracy, general
quality, ease of use, and distribution and dissemination of flood
insurance rate maps and risk data; and (b) performance metrics and
milestones required to effectively and efficiently map flood risk areas
in the United States; (2) mapping standards and guidelines for (a)
flood insurance rate maps, and (b) data accuracy, data quality, data
currency, and data eligibility; (3) how to maintain, on an ongoing
basis, flood insurance rate maps and flood risk identification; (4)
procedures for delegating mapping activities to State and local mapping
partners; and (5) (a) methods for improving interagency and
intergovernmental coordination on flood mapping and flood risk
determination, and (b) a funding strategy to leverage and coordinate
budgets and expenditures across Federal agencies. Furthermore, the TMAC
is required to submit an annual report to the FEMA Administrator that
contains: (1) a description of the activities of the Council; (2) an
evaluation of the status and performance of flood insurance rate maps
and mapping activities to revise and update Flood Insurance Rate Maps;
and (3) a summary of recommendations made by the Council to the FEMA
Administrator.
    Agenda: The purpose of this meeting is for the TMAC members to
discuss the content of the 2023 TMAC Annual Report. Any related
materials will be available upon request prior to the meeting to
provide the public with an opportunity to review the materials. The
full agenda and related meeting materials will be available upon
request by Tuesday, September 12, 2023. To receive a copy of any
relevant materials, please send the request to: [email protected]
(Attn: Brian Koper).

Nicholas A. Shufro,
Deputy Assistant Administrator for Risk Management, Federal Insurance
and Mitigation Administration, Resilience, Federal Emergency Management
Agency.
[FR Doc. 2023-18039 Filed 8-21-23; 8:45 am]
BILLING CODE 9110-12-P


[Federal Register Volume 80, Number 138 (Monday, July 20, 2015)]
[Notices]
[Pages 42828-42829]
[FR Doc No: 2015-17730]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2015-N-2412]

Determination That TESSALON (Benzonatate) Capsules and Other Drug
Products Were Not Withdrawn From Sale for Reasons of Safety or
Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) has determined that the
drug products listed in this document were not withdrawn from sale for
reasons of safety or effectiveness. This determination means that FDA
will not begin procedures to withdraw approval of abbreviated new drug
applications (ANDAs) that refer to these drug products, and it will
allow FDA to continue to approve ANDAs that refer to the products as
long as they meet relevant legal and regulatory requirements.

FOR FURTHER INFORMATION CONTACT: Stacy Kane, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 51, Rm. 6207, Silver Spring, MD 20993-0002,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417)
(the 1984 amendments), which authorized the approval of duplicate
versions of drug products approved under an ANDA procedure. ANDA
sponsors must, with certain exceptions, show that the drug for which
they are seeking approval contains the same active ingredient in the
same strength and dosage form as the ``listed drug,'' which is a
version of the drug that was previously approved. ANDAs applicants do
not have to repeat the extensive clinical testing otherwise necessary
to gain approval of a new drug application (NDA).
    The 1984 amendments include what is now section 505(j)(7) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which
requires FDA to publish a list of all approved drugs. FDA publishes
this list as part of the ``Approved Drug Products with Therapeutic
Equivalence Evaluations,'' which is generally known as the ``Orange
Book.'' Under FDA regulations, a drug is removed from the list if the
Agency withdraws or suspends approval of the drug's NDA or ANDA for
reasons of safety or effectiveness, or if FDA determines that the
listed drug was withdrawn from sale for reasons of safety or
effectiveness (21 CFR 314.162).
    Under Sec.  314.161(a) (21 CFR 314.161(a)), the Agency must
determine whether a listed drug was withdrawn from sale for reasons of
safety or effectiveness: (1) Before an ANDA that refers to that listed
drug may be approved, (2) whenever a listed drug is voluntarily
withdrawn from sale and ANDAs that refer to the listed drug have been
approved, and (3) when a person petitions for such a determination
under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if
FDA determines that a listed drug was withdrawn from sale for safety or
effectiveness reasons, the Agency will initiate proceedings that could
result in the withdrawal of approval of the ANDAs that refer to the
listed drug.
    FDA has become aware that the drug products listed in the table are
no longer being marketed. (As requested by the applicant, FDA withdrew
approval of NDA 050448 for GRIFULVIN (griseofulvin) Oral Suspension in
the Federal Register of August 16, 2001 (66 FR 43017)).

------------------------------------------------------------------------
    Application No.                Drug                  Applicant
------------------------------------------------------------------------
NDA 011210.............  TESSALON (benzonatate)   Pfizer Inc., 1 Giralda
                          Capsule; Oral 200        Farms, Madison, NJ
                          milligrams (mg).         07940.
NDA 012093.............  ISORDIL (isosorbide      Valeant
                          dinitrate) Tablet;       Pharmaceuticals North
                          Oral 10 mg, 20 mg, 30    America, LLC, 400
                          mg.                      Somerset Corporate
                                                   Blvd., Bridgewater,
                                                   NJ 08807.
NDA 018702.............  ACLOVATE (alclometasone  Fougera
                          dipropionate)            Pharmaceuticals Inc.,
                          Ointment; Topical        60 Baylis Rd., P.O.
                          0.05%.                   Box 2006, Melville,
                                                   NY 11747.
NDA 018707.............  ACLOVATE (alclometasone  Do.
                          dipropionate) Cream;
                          Topical 0.05%.
NDA 018936.............  SARAFEM (fluoxetine      Eli Lilly and Co.,
                          hydrochloride (HCl))     Lilly Corp. Ctr.,
                          Capsule; Oral            Indianapolis, IN
                          Equivalent to (EQ) 10    46285.
                          mg Base, EQ 20 mg Base.
NDA 018988.............  VASOCIDIN (prednisolone  Novartis
                          sodium phosphate;        Pharmaceuticals
                          sulfacetamide sodium),   Corp., 105 Eisenhower
                          Solution/Drops;          Pky., 280 Corporate
                          Ophthalmic, EQ 0.23%     Center, Roseland, NJ
                          phosphate; 10%.          07068.
NDA 019898.............  PRAVACHOL (pravastatin   Bristol-Myers Squibb
                          sodium) Tablet; Oral     Co., P.O. Box 4000,
                          10 mg.                   Princeton, NJ 08543-
                                                   4000.
NDA 020092.............  DILACOR XR (diltiazem    Actavis Laboratories
                          HCl) Capsule, Extended-  UT, Inc., 577 Chipeta
                          Release; Oral 120 mg,    Way, Salt Lake City,
                          180 mg, 240 mg.          UT 84108.
NDA 021551.............  HALFLYTELY               Braintree
                          (polyethylene glycol     Laboratories, Inc.,
                          3350; potassium          60 Columbia St., P.O.
                          chloride; sodium         Box 850929,
                          bicarbonate; sodium      Braintree, MA 02185.
                          chloride) For Solution
                          and bisacodyl Delayed-
                          Release Tablets); Oral
                          210 grams (g); 0.74 g;
                          2.86 g; 5.6 g; 5 mg.
NDA 021871.............  LOESTRIN 24 FE (ethinyl  Warner Chilcott Co.
                          estradiol;               LLC, Union Street Rd.
                          norethindrone acetate)   195 KM 1.1., Fajardo,
                          Tablet; Oral 0.02 mg;    Puerto Rico 00738.
                          1 mg.
NDA 050448.............  GRIFULVIN V              Johnson & Johnson
                          (griseofulvin,           Consumer Products
                          microcrystalline)        Co., 199 Grandview
                          Suspension; Oral 125     Rd., Skillman, NJ
                          mg/5 milliliters (mL).   08558.
NDA 050719.............  HELIDAC (bismuth         Prometheus
                          subsalicylate;           Laboratories Inc.,
                          metronidazole;           9410 Carroll Park
                          tetracycline HCl)        Dr., San Diego, CA
                          Tablet, Chewable,        92121.
                          Tablet, Capsule; Oral
                          262.4 mg; 250 mg, 500
                          mg.
ANDA 040454............  PROMETHAZINE             Teva Pharmaceuticals
                          HYDROCHLORIDE            USA, 425 Privet Rd.,
                          (promethazine HCl)       Horsham, PA 19044.
                          Injectable; Injection
                          25 mg/mL, 50 mg/mL.
ANDA 062483............  GRIFULVIN V              Valeant
                          (griseofulvin,           Pharmaceuticals
                          microsize) Suspension;   Luxembourg S.a.r.l, C/
                          Oral 125 mg/5 mL.        O Valeant
                                                   Pharmaceuticals North
                                                   America LLC, 400
                                                   Somerset Corporate
                                                   Blvd., Bridgewater,
                                                   NJ 08807.

ANDA 088762............  PROMETH W/               G&W Laboratories
                          DEXTROMETHORPHAN         Inc.,111 Coolidge
                          (dextromethorphan        St., South
                          hydrobromide;            Plainfield, NJ 07080.
                          promethazine HCl)
                          Syrup; Oral 15 mg/5
                          mL; 6.25 mg/5 mL.
------------------------------------------------------------------------

    FDA has reviewed its records and, under Sec.  314.161, has
determined that the drug products listed in this document were not
withdrawn from sale for reasons of safety or effectiveness.
Accordingly, the Agency will continue to list the drug products listed
in this document in the ``Discontinued Drug Product List'' section of
the Orange Book. The ``Discontinued Drug Product List'' identifies,
among other items, drug products that have been discontinued from
marketing for reasons other than safety or effectiveness.
    Approved ANDAs that refer to the NDAs and ANDAs listed in this
document are unaffected by the discontinued marketing of the products
subject to those NDAs and ANDAs. Additional ANDAs that refer to these
products may also be approved by the Agency if they comply with
relevant legal and regulatory requirements. If FDA determines that
labeling for these drug products should be revised to meet current
standards, the Agency will advise ANDA applicants to submit such
labeling.

    Dated: July 15, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-17730 Filed 7-17-15; 8:45 am]
 BILLING CODE 4164-01-P


[Federal Register Volume 78, Number 181 (Wednesday, September 18, 2013)]
[Notices]
[Pages 57395-57396]
[FR Doc No: 2013-22645]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-D-0643]

Guidance for Industry on Electronic Source Data in Clinical
Investigations; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a guidance for industry entitled ``Electronic Source
Data in Clinical Investigations.'' This document provides guidance to
sponsors, contract research organizations (CROs), clinical
investigators, and others involved in the capture, review, and
retention of electronic source data in FDA-regulated clinical
investigations. This guidance promotes capturing source data in
electronic form, and it is intended to assist in ensuring the
reliability, quality, integrity, and traceability of data from
electronic source to electronic regulatory submission.

DATES: Submit either electronic or written comments on Agency guidances
at any time.

ADDRESSES: Submit written requests for single copies of this guidance
to the Division of Drug Information, Center for Drug Evaluation and
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
51, Rm. 2201, Silver Spring, MD 20993-0002, or the Office of
Communication, Outreach and Development (HFM-40), Center for Biologics
Evaluation and Research (CBER), Food and Drug Administration, 1401
Rockville Pike, Suite 200N, Rockville, MD 20852-1448 (the guidance may
also be obtained by mail by calling CBER at 1-800-835-4709 or 301-827-
1800); or the Division of Small Manufacturers, International and

Consumer Assistance, Center for Devices and Radiological Health, Food
and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 4613,
Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to
assist that office in processing your requests. See the SUPPLEMENTARY
INFORMATION section for electronic access to the guidance document.
    Submit electronic comments on the guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA 305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Ron Fitzmartin, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 1160, Silver Spring, MD 20993-0002, 301-
796-5333; or Jonathan Helfgott, Center for Drug Evaluation and
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
51, Rm. 5369, Silver Spring, MD 20993-0002,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of a guidance for industry
entitled ``Electronic Source Data in Clinical Investigations.'' This
document provides guidance to sponsors, CROs, clinical investigators,
and others involved in the capture, review, and retention of electronic
source data in FDA-regulated clinical investigations. This guidance
promotes capturing source data in electronic form, and it is intended
to assist in ensuring the reliability, quality, integrity, and
traceability of data from electronic source to electronic regulatory
submission.
    With the use of computerized systems for capturing clinical study
data, it is common to find at least some source data recorded
electronically. Common examples include, but are not limited to,
clinical data initially recorded in electronic health records
maintained by healthcare providers and institutions, electronic
laboratory reports, electronic medical images from devices, and
electronic diaries completed by study subjects.
    Capturing source data electronically and transmitting it to the
electronic case report form (eCRF) should help to: (1) Eliminate
unnecessary duplication of data; (2) reduce the possibility for
transcription errors; (3) encourage entering source data during a
subject's visit, where appropriate; (4) eliminate transcription of
source data prior to entry into an eCRF; (5) facilitate remote
monitoring of data; (6) promote real-time access for data review; and
(7) facilitate the collection of accurate and complete data.
    In the Federal Register of November 20, 2012 (77 FR 69632), FDA
issued a draft version of this guidance entitled ``Electronic Source
Data in Clinical Investigations.'' The comment period on the draft
guidance ended on March 26, 2013 (see the correction notice of December
26, 2012 (77 FR 76049)). Most of the comments sought clarification on
the topics discussed in the guidance. We have reviewed all comments
received on the draft guidance. As a result of the public comments, we
have clarified the following sections of the guidance: I. Introduction,
II. Background, III. Electronic Source Data (and its subsections), and
IV. Use and Description of Computerized Systems in Clinical
Investigations. We have also updated the Glossary definitions, added a
References section, and added reference citations throughout the
guidance.
    This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). This guidance represents the
Agency's current thinking on the capture, review, and retention of
electronic source data in FDA-regulated clinical investigations. It
does not create or confer any rights for or on any person and does not
operate to bind FDA or the public. An alternative approach may be used
if such approach satisfies the requirements of the applicable statutes
and regulations.

II. Comments

    Interested persons may submit either electronic comments regarding
this document to http://www.regulations.gov or written comments to the
Division of Dockets Management (see ADDRESSES). It is only necessary to
send one set of comments. Identify comments with the docket number
found in brackets in the heading of this document. Received comments
may be seen in the Division of Dockets Management between 9 a.m. and 4
p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.

III. Paperwork Reduction Act of 1995

    This guidance refers to collections of information that are subject
to review by the Office of Management and Budget (OMB) under the
Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). This guidance
pertains to sponsors, clinical investigators, CROs, and others involved
in the capture, review, and retention of electronic source data in FDA-
regulated clinical investigations and who send certain information to
FDA or others, or who keep certain records and make them available to
FDA inspectors. The information collection discussed in the guidance is
contained in our investigational new drug regulations in part 312 (21
CFR part 312) and approved under OMB control number 0910-0014,
including Sec. Sec.  312.62(b) and 312.58(a). In addition, the
collection of information in 21 CFR part 11, as discussed in the
guidance, is approved under OMB control number 0910-0303. OMB approval
of the information collection in the guidance entitled ``Computerized
Systems Used in Clinical Investigations,'' as mentioned in the
guidance, is discussed in the May 10, 2007 (72 FR 26638), Federal
Register Notice of Availability of that guidance. The capture, review,
and retention of electronic source data, as described in this guidance,
would not result in any new costs, including capital costs or operating
and maintenance costs, because sponsors and others already have and are
experienced with using the computer-based equipment and software
necessary to be consistent with the guidance.

IV. Electronic Access

    Persons with access to the Internet may obtain the document at
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm, http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm, http://www.fda.gov/RegulatoryInformation/Guidances/default.htm, or http://www.regulations.gov.

    Dated: September 12, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-22645 Filed 9-17-13; 8:45 am]
BILLING CODE 4160-01-P


[Federal Register Volume 83, Number 224 (Tuesday, November 20, 2018)]
[Rules and Regulations]
[Pages 58468-58470]
[FR Doc No: 2018-25183]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA-2018-0246; Airspace Docket No. 18-ASW-6]
RIN 2120-AA66

Revocation of Class D and E Airspace; Fort Sill; and Amendment of
Class D and E Airspace; Lawton, OK

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: This action removes Class D airspace, Class E airspace
designated as a surface area, and Class E airspace designated as an
extension to a Class D and Class E airspace at Henry Post Army Air
Field (AAF), Fort Sill, OK; amends Class D airspace and Class E
airspace designated as a surface area at Lawton-Fort Sill Regional
Airport, Lawton, OK; and amends Class E airspace extending upward from
700 feet above the surface at Lawton-Fort Sill Regional Airport and
Henry Post AAF. This action is due to the closure of the air traffic
control tower (ATCT) at Henry Post AAF. The name of Lawton-Fort Sill
Regional Airport and the geographic coordinates of Henry Post AAF are
also being updated to coincide with the FAA's aeronautical database,
and the outdated term ``Airport/Facility Directory'' is replaced with
the term ``Chart Supplement.''

DATES: Effective 0901 UTC, February 28, 2019. The Director of the
Federal Register approves this incorporation by reference action under
Title 1 Code of Federal Regulations part 51, subject to the annual
revision of FAA Order 7400.11 and publication of conforming amendments.

ADDRESSES: FAA Order 7400.11C, Airspace Designations and Reporting
Points, and subsequent amendments can be viewed online at http://www.faa.gov/air_traffic/publications/. For further information, you can
contact the Airspace Policy Group, Federal Aviation Administration, 800
Independence Avenue SW, Washington, DC 20591; telephone: (202) 267-
8783. The Order is also available for inspection at the National
Archives and Records Administration (NARA). For information on the
availability of FAA Order 7400.11C at NARA, call<PHONE_NUMBER>, or go
to https://www.archives.gov/federal-register/cfr/ibr-locations.html.
    FAA Order 7400.11, Airspace Designations and Reporting Points, is
published yearly and effective on September 15.

FOR FURTHER INFORMATION, CONTACT: Jeffrey Claypool, Federal Aviation
Administration, Operations Support Group, Central Service Center, 10101
Hillwood Parkway, Fort Worth, TX 76177; telephone<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

Authority for This Rulemaking

    The FAA's authority to issue rules regarding aviation safety is
found in Title 49 of the United States Code. Subtitle I, Section 106
describes the authority of the FAA Administrator. Subtitle VII,
Aviation Programs, describes in more detail the scope of the agency's
authority. This rulemaking is promulgated under the authority described
in Subtitle VII, Part A, Subpart I, Section 40103. Under that section,
the FAA is charged with prescribing regulations to assign the use of
airspace necessary to ensure the safety of aircraft and the efficient
use of airspace. This regulation is within the scope of that authority
as it removes Class D airspace, Class E airspace designated as a
surface area, and Class E airspace designated as an extension to a
Class D and Class E airspace at Henry Post AAF, Fort Sill, OK; amends
Class D airspace and Class E airspace designated as a surface area at
Lawton-Fort Sill Regional Airport, Lawton, OK; and amends Class E
airspace extending upward from 700 feet above the surface at Lawton-
Fort Sill Regional Airport and Henry Post AAF to support instrument
flight rule operations at these airports.

History

    The FAA published a notice of proposed rulemaking (NPRM) in the
Federal Register (83 FR 22889; May 17, 2018) for Docket No. FAA-2018-
0246 to remove Class D airspace, Class E airspace designated as a
surface area, and Class E airspace designated as an extension to a
Class D and Class E airspace at Henry Post AAF, Fort Sill, OK; amend
Class D airspace and Class E airspace designated as a surface area at
Lawton-Fort Sill Regional Airport, Lawton, OK; and amend Class E
airspace extending upward from 700 feet above the surface at Lawton-
Fort Sill Regional Airport and Henry Post AAF. Interested parties were
invited to participate in this rulemaking effort by submitting written
comments on the proposal to the FAA. No comments were received.
    Subsequent to publication, the FAA found a typographic error in the
in the airspace legal description for the Class E airspace extending
upward from 700 feet above the surface at Lawton-Fort Sill Regional
Airport, Lawton, OK. The extension to the south from the Lawton VOR/DME
was incorrectly stated from the 6.9-mile radius, instead of the 6.8-
mile radius, and is corrected in this rule.
    Class D and E airspace designations are published in paragraphs
5000, 6002, 6004, and 6005, respectively, of FAA Order 7400.11C, dated
August 13, 2018, and effective September 15, 2018, which is
incorporated by reference in 14 CFR 71.1. The Class D and E airspace
designations listed in this document will be published subsequently in
the Order.

Availability and Summary of Documents for Incorporation by Reference

    This document amends FAA Order 7400.11C, Airspace Designations and
Reporting Points, dated August 13, 2018, and effective September 15,
2018. FAA Order 7400.11C is publicly available as listed in the
ADDRESSES section of this document. FAA Order 7400.11C lists Class A,
B, C, D, and E airspace areas, air traffic service routes, and
reporting points.

The Rule

    This rule amends Title 14 Code of Federal Regulations (14 CFR) part
71 by:
    Removing Class D airspace at Henry Post AAF, Fort Sill, OK;
    Amending Class D airspace at Lawton-Fort Sill Regional Airport
(formerly Lawton Municipal Airport), Lawton, OK, by adding an extension
1.1 miles each side of the 167[deg] radial of the Lawton VOR/DME
extending from the 4.3-mile radius to 5.3 miles south of the airport;
amending the exclusionary language from ``that airspace north of a line
between lat. 34[deg]36'18'' N, long. 98[deg]20'33'' W and lat.
34[deg]37'16'' N, long. 98[deg]28'29'' W to ``that airspace within a 2-
mile radius of Henry Post AAF''; updating the name of the airport to
coincide with the FAA's aeronautical database; and making an editorial
change to the legal description replacing ``Airport/Facility
Directory'' with ``Chart Supplement'';
    Removing Class E airspace designated as a surface area at Henry
Post AAF;
    Amending Class E airspace designated as a surface area at Lawton-
Fort Sill Regional Airport by adding an extension 1.1 miles each side
of the 167[deg] radial of the Lawton VOR/DME extending from the 4.3-
mile radius to 5.3 miles south of the airport; removing that area
within a 4-mile radius of Henry Post AAF from the airspace legal
description; amending the exclusionary language from ``within
Restricted Areas R5601A and R-5601B when these restricted areas are
activated'' to ``that airspace within a 2-mile radius of Henry Post
AAF''; updating the name of the Lawton-Fort Sill Airport (formerly
Lawton Municipal Airport), and the geographic coordinates of Henry Post
AAF to coincide with the FAA's aeronautical database; removing the city
name associated with Henry Post AAF to comply with FAA Order 7400.2L,
Procedures for Handling Airspace Matters; and making an editorial
change to the legal description replacing ``Airport/Facility
Directory'' with ``Chart Supplement'';
    Removing Class E airspace designated as an extension of Class D and
Class E airspace at Henry Post AAF; and

    Amending Class E airspace extending upward from 700 feet above the
surface at Lawton-Fort Sill Regional Airport and Henry Post AAF by
amending the extension to the south of Lawton-Fort Sill Regional
Airport from the 167[deg] (previously 178[deg]) radial from the Lawton
VOR/DME extending from the 6.8-mile radius to 13.1 (decreased from
20.6) miles south of the Lawton-Fort Sill Regional Airport; removing
the extension from the 358[deg] radial from Lawton VOR/DME; removing
the extension to the north of Henry Post AAF referencing the 003[deg]
radial from the Lawton VOR/DME; adding an extension 4 miles each side
of the 360[deg] bearing from the Henry Post AAF from the 6.5-mile
radius of Henry Post AAF to 10.9 miles north of Henry Post AAF;
amending the exclusionary language pertaining to restricted areas from
``R-5601A and R-5601B when these restricted areas are activated'' to
``R-5601A, R-5601B and R-5601H when active''; removing the exclusionary
language ``and excluding that airspace within the Wichita Falls, TX,
Class E airspace area'' from the airspace legal description; and
updating the name of Lawton-Fort Sill Regional (formerly Lawton
Municipal Airport) and the geographic coordinates of Henry Post AAF to
coincide with the FAA's aeronautical database.
    The typographical error in the airspace legal description for the
Class E airspace extending upward from 700 feet above the surface at
Lawton-Ft. Sill Regional Airport, Lawton, OK, is corrected as follows:
The extension to the south from the Lawtwon VOR/DME is corrected to
extend from a ``6.8-mile radius'' instead of a ``6.9-mile radius.''
Except for this change, this rule is the same as published in the NPRM.
    This action is due to the closure of the ATCT at Henry Post AAF and
to remove the associated airspace.

Regulatory Notices and Analyses

    The FAA has determined that this regulation only involves an
established body of technical regulations for which frequent and
routine amendments are necessary to keep them operationally current, is
non-controversial and unlikely to result in adverse or negative
comments. It, therefore: (1) Is not a ``significant regulatory action''
under Executive Order 12866; (2) is not a ``significant rule'' under
DOT Regulatory Policies and Procedures (44 FR 11034; February 26,
1979); and (3) does not warrant preparation of a regulatory evaluation
as the anticipated impact is so minimal. Since this is a routine matter
that only affects air traffic procedures and air navigation, it is
certified that this rule, when promulgated, does not have a significant
economic impact on a substantial number of small entities under the
criteria of the Regulatory Flexibility Act.

Environmental Review

    The FAA has determined that this action qualifies for categorical
exclusion under the National Environmental Policy Act in accordance
with FAA Order 1050.1F, ``Environmental Impacts: Policies and
Procedures,'' paragraph 5-6.5.a. This airspace action is not expected
to cause any potentially significant environmental impacts, and no
extraordinary circumstances exist that warrant preparation of an
environmental assessment.

Lists of Subjects in 14 CFR Part 71

    Airspace, Incorporation by reference, Navigation (air).

Adoption of the Amendment

    In consideration of the foregoing, the Federal Aviation
Administration amends 14 CFR part 71 as follows:

PART 71--DESIGNATION OF CLASS A, B, C, D, AND E AIRSPACE AREAS; AIR
TRAFFIC SERVICE ROUTES; AND REPORTING POINTS

0
1. The authority citation for part 71 continues to read as follows:

    Authority: 49 U.S.C. 106(f), 106(g); 40103, 40113, 40120; E.O.
10854, 24 FR 9565, 3 CFR, 1959-1963 Comp., p. 389.

Sec.  71.1  [Amended]

0
2. The incorporation by reference in 14 CFR 71.1 of FAA Order 7400.11B,
Airspace Designations and Reporting Points, dated August 3, 2017, and
effective September 15, 2017, is amended as follows:

Paragraph 5000 Class D Airspace.

* * * * *

ASW OK D Fort Sill, OK [Removed]

ASW OK D Lawton, OK [Amended]

Lawton-Fort Sill Regional Airport, OK
    (Lat. 34[deg]34'04'' N, long. 98[deg]25'00'' W)
Lawton VOR/DME
    (Lat. 34[deg]29'46'' N, long. 98[deg]24'47'' W)
Henry Post AAF
    (Lat. 34[deg]38'59'' N, long. 98[deg]24'08'' W)

    That airspace extending upward from the surface to and including
3,700 feet MSL within a 4.3-mile radius of Lawton-Fort Sill Regional
Airport, and within 1.1 miles each side of the 167[deg] radial from
the Lawton VOR/DME extending from the 4.3-mile radius to 5.3 miles
south of the airport, excluding that airspace within a 2-mile radius
of Henry Post AAF. This Class D airspace area is effective during
the specific dates and times established in advance by a Notice to
Airmen. The effective date and time will thereafter be continuously
published in the Chart Supplement.

Paragraph 6002 Class E Airspace Areas Designated as Surface Areas.

* * * * *

ASW OK E2 Fort Sill, OK [Removed]

* * * * *

ASW OK E2 Lawton, OK [Amended]

Lawton-Fort Sill Regional Airport, OK
    (Lat. 34[deg]34'04'' N, long. 98[deg]25'00'' W)
Lawton VOR/DME
    (Lat. 34[deg]29'46'' N, long. 98[deg]24'47'' W)
Henry Post AAF
    (Lat. 34[deg]38'59'' N, long. 98[deg]24'08'' W)

    That airspace extending upward from the surface to and including
3,700 feet MSL within a 4.3-mile radius of Lawton-Fort Sill Regional
Airport, and within 1.1 miles each side of the 167[deg] radial from
the Lawton VOR/DME extending from the 4.3-mile radius to 5.3 miles
south of the airport, excluding that airspace within a 2-mile radius
of Henry Post AAF. This Class E airspace area is effective during
the specific dates and times established in advance by a Notice to
Airmen. The effective date and time will thereafter be continuously
published in the Chart Supplement.

Paragraph 6004 Class E Airspace Designated as an Extension of Class
D and Class E Surface Areas.

* * * * *

ASW OK E4 Fort Sill, OK [Removed]

Paragraph 6005 Class E Airspace Areas Extending Upward From 700
Feet or More Above the Surface of the Earth.

* * * * *

ASW OK E5 Lawton, OK [Amended]

Lawton-Fort Sill Regional Airport, OK
    (Lat. 34[deg]34'04'' N, long. 98[deg]25'00'' W)
Lawton VOR/DME
    (Lat. 34[deg]29'46'' N, long. 98[deg]24'47'' W)
Henry Post AAF
    (Lat. 34[deg]38'59'' N, long. 98[deg]24'08'' W)

    That airspace extending upward from 700 feet above the surface
within a 6.8-mile radius of Lawton-Fort Sill Regional Airport, and
within 4 miles each side of the 167[deg] radial from the Lawton VOR/
DME extending from the 6.8-mile radius to 13.1 miles south of
Lawton-Fort Sill Regional Airport, and within a 6.5-mile radius of
Henry Post AAF, and within 4 miles each side of the 360[deg] bearing
from Henry Post AAF extending from the 6.5-mile radius to 10.9 miles
north of Henry AAF, excluding that airspace within Restricted Areas
R-5601A, R-5601B, and R-5601H when active.

    Issued in Fort Worth, Texas, on November 8, 2018.
Walter Tweedy,
Acting Manager, Operations Support Group, ATO Central Service Center.
[FR Doc. 2018-25183 Filed 11-19-18; 8:45 am]
BILLING CODE 4910-13-P